miRNA assays

The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.

The New York State Department of Health had previously provided conditional approval of the microRNA classifier for diagnosing indeterminate thyroid cancer cases.

After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly. 

The company said that given recent debt restructuring efforts and certain regulatory and payor approvals of its products, it's on track for a strong 2017.

Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.

The team recently received funding to develop and validate an assay to help guide clinical decision making when pancreatic cancer precursor lesions are detected.

Abcam was encouraged to buy Firefly BioWorks by its customers, who are more frequently complementing their protein analysis work with miRNA studies.

NEW YORK (GenomeWeb) – Rosetta Genomics today announced a deal to sell tests from Admera Health to oncologists and pathologists.

NEW YORK (GenomeWeb) – Rosetta Genomics reported after the close of the market on Wednesday a sharp increase in its revenues for the first half of 2014.

NEW YORK (GenomeWeb) – Firefly BioWorks said in a document filed with the US Securities and Exchange Commission that it has raised $775,000 toward a targeted amount of $1.5 million.

Pages

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.